Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver

World Journal of Gastroenterology

Volumn 19, Issue 42, 2013, Pages 7327-7340

  Rojas Feria, María ^a   Castro, Manuel ^a   Suárez, Emilio ^a   Ampuero, Javier ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Drug induced liver injury; Extraintestinal manifestations; Hepatitis B; Hepatitis C; Hepatobiliary disorders; Hepatotoxicity; Inflammatory bowel disease; Primary sclerosing cholangitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ALANINE AMINOTRANSFERASE; AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G4; INFLIXIMAB; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; TENOFOVIR; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID;

ACUTE PANCREATITIS; AMYLOIDOSIS; ARTHRALGIA; BILE DUCT CARCINOMA; BILE DUCT DISEASE; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CHOLELITHIASIS; DRUG HYPERSENSITIVITY; ENTERITIS; FEVER; GRANULOMATOUS HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; ILEITIS; IMMUNOGLOBULIN G4 RELATED DISEASE; KIDNEY DISEASE; LIVER ABSCESS; LIVER FUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUPUS LIKE SYNDROME; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS (TOPIC); MYALGIA; NEUROLOGIC DISEASE; NODULAR HYPERPLASIA; NONALCOHOLIC FATTY LIVER; OPPORTUNISTIC INFECTION; PANCREATITIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PURPURA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SMALL DUCT PRIMARY SCLEROSING CHOLANGITIS; TOXIC HEPATITIS; ULCERATIVE COLITIS; VEIN OCCLUSION; VIRUS LOAD; VIRUS REACTIVATION;

DRUG-INDUCED LIVER INJURY; EXTRAINTESTINAL MANIFESTATIONS; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISORDERS; HEPATOTOXICITY; INFLAMMATORY BOWEL DISEASE; PRIMARY SCLEROSING CHOLANGITIS;

ANIMALS; BILIARY TRACT DISEASES; COMBINED MODALITY THERAPY; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LIVER; LIVER DISEASES; PATIENT CARE TEAM; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887595914     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i42.7327     Document Type: Review

References (142)

1. Smith MP, Loe RH. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 1965; 110: 239-246. [PMID: 14313190 DOI: 10.1016/0002-9610(65)90018-8]
2. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41. [PMID: 16496231 DOI: 10.1055/s-2006-933561]
3. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, Mac-Carty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-436. [PMID: 2777204 DOI: 10.1002/hep.1840100406]
4. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Yawn BP, Dickson ER, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369. [PMID: 14598252 DOI: 10.1016/ j.gastro.2003.07.011]
5. Escorsell A, Parés A, Rodés J, Solís-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21: 787-791. [PMID: 7890895 DOI: 10.1016/ S0168-8278(94)80240-8]
6. Tung BY, Brentnall TA, Kowdley KV, Emond M, Kimmey MB, Stevens AC, Rubin CE, Haggitt RC. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24: 169A
7. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-933. [PMID: 7877651 DOI: 10.1056/ NEJM199504063321406]
8. Joo M, Abreu-e-Lima P, Farraye F, Smith T, Swaroop P, Gardner L, Lauwers GY, Odze RD. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-862. [PMID: 19295408 DOI: 10.1097/PAS.0b013e318196d018]
9. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Lööf LA, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-943. [PMID: 18674735 DOI: 10.1016/j.cgh.2008.03.016]
10. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, Eddleston AL, Williams R. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390-395. [PMID: 1639348 DOI: 10.1002/hep.1840160217]
11. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995; 108: 870-878. [PMID: 7875491 DOI: 10.1016/0016-5085(95)90463-8]
12. Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismüller TJ, Wedemeyer J, Schramm C, Sterneck M, Günther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen CY, Schreiber S, Karlsen TH, Franke A, Weersma RK. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011; 53: 1977-1985. [PMID: 21425313 DOI: 10.1002/hep.24307]
13. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-417. [PMID: 8444414 DOI: 10.1002/ hep.1840170310]
14. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996; 38: 384-389. [PMID: 8675091 DOI: 10.1136/gut.38.3.384]
15. Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 2005; 28: 115-133. [PMID: 15879618 DOI: 10.1385/ CRIAI:28:2:115]
16. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, Lindor KD. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32: 182-187. [PMID: 10707856 DOI: 10.1016/ S0168-8278(00)80061-6]
17. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005; 4: 137-143. [PMID: 15823499 DOI: 10.1016/j.autrev.2004.09.003]
18. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96. [PMID: 15591511 DOI: 10.1136/gut.2004.046615]
19. Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-847. [PMID: 11231938 DOI: 10.1053/gast.2001.22434]
20. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-239. [PMID: 8801203 DOI: 10.1136/ gut.38.2.234]
21. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54. [PMID: 12085034 DOI: 10.1067/mge.2002.125367]
22. Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-456. [PMID: 9106695 DOI: 10.1007/ BF02258391]
23. Navaneethan U, Venkatesh PG, Mukewar S, Lashner BA, Remzi FH, McCullough AJ, Kiran RP, Shen B, Fung JJ. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 540-546. [PMID: 22245961 DOI: 10.1016/j.cgh.2012.01.006]
24. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-1228. [PMID: 21402617 DOI: 10.1136/gut.2010.235408]
25. Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract 2012; 2012: 642923. [PMID: 22474447 DOI: 10.1155/2012/642923]
26. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48: 598-605. [PMID: 18222013 DOI: 10.1016/j.jhep.2007.11.019]
27. Moff SL, Kamel IR, Eustace J, Lawler LP, Kantsevoy S, Kalloo AN, Thuluvath PJ. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64: 219-223. [PMID: 16860072 DOI: 10.1016/j.gie.2005.12.034]
28. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678. [PMID: 20101749 DOI: 10.1002/hep.23294]
29. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1: 632-640. [PMID: 7308996 DOI: 10.1002/hep.1840010612]
30. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzén H, Wallerstedt S, Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615. [PMID: 8707097 DOI: 10.1136/gut.38.4.610]
31. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 1092-107; quiz e135. [PMID: 21893134 DOI: 10.1016/j.cgh.2011.08.027]
32. Navaneethan U, Venkatesh PG, Lashner BA, Shen B, Kiran RP. The Impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012; Epub ahead of print. [PMID: 22428605 DOI: 10.1111/j.1365-2036.2012.05063]
33. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, Lindor KD, Dickson ER. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-694. [PMID: 10907383]
34. Kato T, Komori A, Bae SK, Migita K, Ito M, Motoyoshi Y, Abiru S, Ishibashi H. Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis. World J Gastroenterol 2012; 18: 192-196. [PMID: 22253527 DOI: 10.3748/wjg.v18.i2.192]
35. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327. [PMID: 11867174 DOI: 10.1016/ S0168-8278(01)00288-4]
36. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526. [PMID: 15056096 DOI: 10.1111/j.1572-0241.2004.04067.x]
37. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45: 568-574. [PMID: 16879890 DOI: 10.1016/ j.jhep.2006.05.010]
38. Marsh JW, Iwatsuki S, Makowka L, Esquivel CO, Gordon RD, Todo S, Tzakis A, Miller C, Van Thiel D, Starzl TE. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg 1988; 207: 21-25. [PMID: 2827593 DOI: 10.1097/00000658-198801000-00005]
39. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, Hay JE, Gores GJ, Charlton MR, Ludwig J, Poterucha JJ, Steers JL, Krom RA. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-1056. [PMID: 10094945 DOI: 10.1002/ hep.510290427]
40. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-912. [PMID: 8404380 DOI: 10.1007/BF02050624]
41. Navaneethan U, Kochhar G, Venkatesh PG, Lewis B, Lashner BA, Remzi FH, Shen B, Kiran RP. Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc 2012; 75: 1045-1054.e1. [PMID: 22405258 DOI: 10.1016/j.gie.2012.01.015]
42. Ståhlberg D, Veress B, Tribukait B, Broomé U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003; 46: 770-778. [PMID: 12794579]
43. Chaparro M, Trapero-Marugán M, Guijarro M, López C, Moreno-Otero R, Gisbert JP. Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohns Colitis 2013; 7: e61-e65. [PMID: 22552273 DOI: 10.1016/j.crohns.2012.04.005]
44. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, Mc-Cashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814. [PMID: 19585548 DOI: 10.1002/hep.23082]
45. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39: 865-873. [PMID: 19467021 DOI: 10.1111/j.1872-034X.2009.00527.x]
46. Ashraf I, Choudhary A, Arif M, Matteson ML, Hammad HT, Puli SR, Bechtold ML. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol 2012; 31: 69-74. [PMID: 22528343 DOI: 10.1007/ s12664-012-0175-3]
47. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-1127. [PMID: 10534330]
48. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53: 308-312. [PMID: 11231388]
49. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494-1500. [PMID: 12029635 DOI: 10.1053/ jhep.2002.33202]
50. Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-980. [PMID: 18395078 DOI: 10.1053/ j.gastro.2008.01.042]
51. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001; 33: 994-1002. [PMID: 11283866 DOI: 10.1053/jhep.2001.23316]
52. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553. [PMID: 11230733 DOI: 10.1053/jhep.2001.22131]
53. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-365. [PMID: 9695997 DOI: 10.1002/hep.510280210]
54. Lüth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, Galle PR, Herkel J, Lohse AW. Characteristics and long-term prognosis of the autoimmune hepatitis/ primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009; 43: 75-80. [PMID: 18769363 DOI: 10.1097/ MCG.0b013e318157c614]
55. Santos OM, Muñoz Ortiz E, Pérez C, Restrepo JC. [Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in adults: report of three cases]. Gastroenterol Hepatol 2012; 35: 254-258. [PMID: 22284044 DOI: 10.1016/ j.gastrohep.2011.12.003]
56. Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn' s disease. Digestion 2010; 82: 24-26. [PMID: 20160443 DOI: 10.1159/000273735]
57. Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013; 58: 326-343. [PMID: 22918690 DOI: 10.1007/ s10620-012-2367-1]
58. Dastis SN, Latinne D, Sempoux C, Geubel AP. Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings. J Hepatol 2009; 51: 601-605. [PMID: 19615774 DOI: 10.1016/j.jhep.2009.05.032]
59. Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46: 277-288. [PMID: 21452084 DOI: 10.1007/s00535-011-0386-x]
60. Hirano K, Kawabe T, Yamamoto N, Nakai Y, Sasahira N, Tsujino T, Toda N, Isayama H, Tada M, Omata M. Serum IgG4 concentrations in pancreatic and biliary diseases. Clin Chim Acta 2006; 367: 181-184. [PMID: 16426597 DOI: 10.1016/ j.cca.2005.11.031]
61. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-2075. [PMID: 16879434 DOI: 10.1111/j.1572-0241.2006.00772.x]
62. Novotný I, Dítě P, Trna J, Lata J, Husová L, Geryk E. Immunoglobulin G4-related cholangitis: a variant of IgG4-related systemic disease. Dig Dis 2012; 30: 216-219. [PMID: 22722442 DOI: 10.1159/000336706]
63. Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms-IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther 2011; 33: 1273-1291. [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x]
64. Silveira MG. IgG4-associated cholangitis. Clin Liver Dis 2013; 17: 255-268. [PMID: 23540501 DOI: 10.1016/j.cld.2012.11.007]
65. Tada F, Abe M, Nunoi H, Azemoto N, Mashiba T, Furukawa S, Kumagi T, Murakami H, Ikeda Y, Matsuura B, Hiasa Y, Onji M. Ulcerative colitis complicated with primary biliary cirrhosis. Intern Med 2011; 50: 2323-2327. [PMID: 22001458 DOI: 10.2169/internalmedicine.50.5919]
66. Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol 2003; 9: 878-880. [PMID: 12679954]
67. Ohge H, Takesue Y, Yokoyama T, Hiyama E, Murakami Y, Imamura Y, Shimamoto F, Matsuura Y. Progression of primary biliary cirrhosis after proctocolectomy for ulcerative colitis. J Gastroenterol 2000; 35: 870-872. [PMID: 11085498 DOI: 10.1007/s005350070026]
68. Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T, Gumaste V, Werther JL, Janowitz HD. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71: 261-270. [PMID: 1522802 DOI: 10.1097/00005792-199209000-00001]
69. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001; 7: 295-300. [PMID: 11720318 DOI: 10.1097/00054725-200111000-00003]
70. Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol 1999; 94: 1973-1974. [PMID: 10406274 DOI: 10.1111/ j.1572-0241.1999.01245.x]
71. Venkatesh PG, Navaneethan U, Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis 2011; 12: 245-256. [PMID: 21791019 DOI: 10.1111/ j.1751-2980.2011.00511.x]
72. Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, Ardizzone S, Porro GB, Sampietro GM, Giorgi R, Moretti R, Gallus S. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45: 1267-1274. [PMID: 17464998 DOI: 10.1002/hep.21537]
73. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-1619. [PMID: 20198712 DOI: 10.1002/ibd.21219]
74. Mibu R, Makino I, Chijiiwa K. Gallstones and their composition in patients with ileoanal anastomosis. J Gastroenterol 1995; 30: 413-415. [PMID: 7647911 DOI: 10.1007/BF02347521]
75. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145. [PMID: 3080643 DOI: 10.1016/ S0025-6196(12)65200-8]
76. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011; 5: 287-294. [PMID: 21683298 DOI: 10.1016/ j.crohns.2011.01.011]
77. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186. [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]
78. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101. [PMID: 14687149 DOI: 10.1046/ j.1572-0241.2003.04026.x]
79. Sinagra E, Aragona E, Romano C, Maisano S, Orlando A, Virdone R, Tesè L, Modesto I, Criscuoli V, Cottone M. The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature. Gastroenterol Res Pract 2012; 2012: 916428. [PMID: 23093957 DOI: 10.1155/2012/916428]
80. Molina Infante J, Bañares Cañizares R, Gómez Camarero J, Pérez Calle JL. [Liver abscess and Crohn' disease. Report of 3 cases]. Gastroenterol Hepatol 2004; 27: 317-319. [PMID: 15117612]
81. Bernabeu JL, Leo E, Trigo C, Herrera JM, Sousa JM, Marquez JL. Crohn's disease and liver abscess due to Pediococcus sp. Inflamm Bowel Dis 2011; 17: 2207-2208. [PMID: 21287670 DOI: 10.1002/ibd.21622]
82. Aguas M, Bastida G, Nos P, Beltrán B, Grueso JL, Grueso J. Septic thrombophlebitis of the superior mesenteric vein and multiple liver abscesses in a patient with Crohn's disease at onset. BMC Gastroenterol 2007; 7: 22. [PMID: 17565671 DOI: 10.1186/1471-230X-7-22]
83. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438. [PMID: 7382552]
84. McGowan CE, Jones P, Long MD, Barritt AS. Changing shape of disease: nonalcoholic fatty liver disease in Crohn' s disease-a case series and review of the literature. Inflamm Bowel Dis 2012; 18: 49-54. [PMID: 21351214 DOI: 10.1002/ ibd.21669]
85. Sourianarayanane A, Garg G, Smith TH, Butt MI, Mc-Cullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7: e279-e285. [PMID: 23158500 DOI: 10.1016/j.crohns.2012.10.015]
86. World Health Organization. Immunization, vaccines and biologicals, hepatitis B. Available from: URL: http://www.who.int/immunization/topics/hepatitis_b/en/index.html Accessed November 11, 2008
87. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46. [PMID: 14768714]
88. Buti M, García-Samaniego J, Prieto M, Rodríguez M, Sánchez-Tapias JM, Suárez E, Esteban R. [Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. Gastroenterol Hepatol 2012; 35: 512-528. [PMID: 22749508 DOI: 10.1016/ j.gastrohep.2012.04.006]
89. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102. [PMID: 18184191 DOI: 10.1111/j.1365-2893.2007.00902.x]
90. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68. [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015]
91. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC, Lin TY. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18: 877-883. [PMID: 21054683 DOI: 10.1111/ j.1365-2893.2010.01386.x]
92. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57: 1177-1185. [PMID: 22871500 DOI: 10.1016/ j.jhep.2012.07.031]
93. Biancone L, Pavia M, Del Vecchio Blanco G, D'Incà R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001; 7: 287-294. [PMID: 11720317]
94. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365. [PMID: 15306601 DOI: 10.1136/gut.2004.040675]
95. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M. Preva-lence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63. [PMID: 19098850 DOI: 10.1038/ajg.2008.4]
96. Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol 2009; 33: 1082-1093. [PMID: 19896313 DOI: 10.1016/ j.gcb.2009.03.021]
97. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology 2009; 50: 653-654. [PMID: 19575458 DOI: 10.1002/hep.23035]
98. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, Park BL, Shin HD. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12: 2541-2546. [PMID: 12915457]
99. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976. [PMID: 16521231 DOI: 10.1093/hmg/ddg262]
100. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-1454. [PMID: 17600380 DOI: 10.1002/ibd.20216]
101. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401. [PMID: 18592158 DOI: 10.1007/s00535-008-2165-x]
102. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163-166. [PMID: 15712655 DOI: 10.1007/s10620-005-1295-8]
103. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-509. [PMID: 17206687 DOI: 10.1002/ibd.20035]
104. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346. [PMID: 20577000 DOI: 10.1136/gut.2010.208413]
105. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
106. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010]
107. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-1466. [PMID: 23034605 DOI: 10.1038/ajg.2012.79]
108. Biancone L, Del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002; 122: 593-594. [PMID: 11845808 DOI: 10.1053/ gast.2002.31602]
109. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Barbosa DV, Lanzoni VP, Ferraz ML, Silva AE. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology 2008; 48: 348-349. [PMID: 18521870 DOI: 10.1002/hep.22331]
110. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395. [PMID: 15776454 DOI: 10.1002/lt.20344]
111. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 52-57. [PMID: 14755778 DOI: 10.1002/lt.20000]
112. Nissen MJ, Fontanges E, Allam Y, Zoulim F, Trépo C, Miossec P. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 2005; 44: 1016-1020. [PMID: 15855185 DOI: 10.1093/ rheumatology/keh668]
113. Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C, Miyake T, Niigaki M, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 390-399. [PMID: 9021719 DOI: 10.1111/j.1600-0676.1996.tb00768.x]
114. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebocontrolled study. J Hepatol 2005; 42: 315-322. [PMID: 15791697 DOI: 10.1016/j.jhep.2004.11.025]
115. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082. [PMID: 14583571 DOI: 10.1136/ard.62.11.1078]
116. Villa F, Rumi MG, Signorelli C, Saibeni S, Del Ninno E, Ferrero Bogetto S, de Franchis R, Vecchi M. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 2005; 17: 1243-1245. [PMID: 16215439 DOI: 10.1097/00042737-200511000-00015]
117. Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 2007; 102: 1333-1334. [PMID: 17531027 DOI: 10.1111/j.1572-0241.2007.01131.x]
118. Salcedo-Mora X, Maté J, Medina J, Nam Cha SJ, Gisbert JP, Moreno-Otero R. Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion 2006; 73: 210-214. [PMID: 16883071 DOI: 10.1159/000094787]
119. Scherzer TM, Staufer K, Novacek G, Steindl-Munda P, Schumacher S, Hofer H, Ferenci P, Vogelsang H. Efficacy and safety of antiviral therapy in patients with Crohn' s disease and chronic hepatitis C. Aliment Pharmacol Ther 2008; 28: 742-748. [PMID: 19145730 DOI: 10.1111/ j.1365-2036.2008.03779.x]
120. Sümer N, Palabiyikoǧlu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 597-602. [PMID: 8590152]
121. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroidrefractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002; 16: 1233-1239. [PMID: 12144572 DOI: 10.1046/j.1365-2036.2002.01264.x]
122. Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2008; (3): CD006790. [PMID: 18646167 DOI: 10.1002/14651858.CD006790.pub2]
123. De Diego Lorenzo A, Kashoob M, Romero M, Parera A, Durán F, Piqueras B, Santos L, Cos E, Clemente G. [Treatment with recombinant interferon alfa-2b of a patient with chronic hepatitis C and concomitant ulcerative colitis]. Rev Esp Enferm Dig 1997; 89: 399-401. [PMID: 9280430]
124. Mitoro A, Yoshikawa M, Yamamoto K, Mimura M, Yoshikawa Y, Shiroi A, Mochi T, Sakamoto T, Yamao J, Kikuchi E. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993; 32: 327-331. [PMID: 8102914 DOI: 10.2169/internalmedicine.32.327]
125. Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005; 22: 209-215. [PMID: 16091058 DOI: 10.1111/j.1365-2036.2005.02556.x]
126. Horn TL, Reynolds J, de Villiers W, Peña LR. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci 2009; 54: 1171-1177. [PMID: 18975088 DOI: 10.1007/s10620-008-0489-2]
127. Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-1114. [PMID: 17455203 DOI: 10.1002/ ibd.20160]
128. Loftus EV, Kane SV, Bjorkman D. Systematic review: shortterm adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-189. [PMID: 14723609 DOI: 10.1111/j.0269-2813.2004.01827. x]
129. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539. [PMID: 12235076 DOI: 10.1136/gut.51.4.536]
130. Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, Lupinacci G, Pirola L, Cucino C, Meucci G, Basilisco G, D'Incà R, Bruno S. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis 2012; 44: 123-127. [PMID: 22051323 DOI: 10.1016/ j.dld.2011.09.015]
131. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3150-3156. [PMID: 11095334 DOI: 10.1111/ j.1572-0241.2000.03287.x]
132. Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can J Gastroenterol 2005; 19: 553-558. [PMID: 16151547]
133. Chande N, Abdelgadir I, Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn's disease. J Clin Gastroenterol 2011; 45: 599-601. [PMID: 21224737 DOI: 10.1097/MCG.0b013e3181f593f9]
134. Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert JP, Moreno-Otero R. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011; 137: 637-639. [PMID: 21719043 DOI: 10.1016/j.medcli.2010.12.024]
135. Dominique L. Liver toxicity of TNFalpha antagonists. Joint Bone Spine 2008; 75: 636-638. [PMID: 18952478 DOI: 10.1016/ j.jbspin.2008.07.005]
136. FDA Briefing Document. Arthritis Advisory Committee (15 Jun 2009). Available from: URL: http://ww.fda.gov/ohrms/ dockets/act/03/transcripts/3930T1.htm
137. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-564.e3. [PMID: 23333219 DOI: 10.1016/j.cgh.2012.12.025]
138. Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Rev Esp Enferm Dig 2012; 104: 282-284. [PMID: 22662786 DOI: 10.4321/S1130-01082012000500014]
139. Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-782. [PMID: 16225485 DOI: 10.1111/j.1365-2036.2005.02636.x]
140. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 287-290. [PMID: 11293451 DOI: 10.1097 /00042737-200103000-00013]
141. Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988; 83: 256-261. [PMID: 3278593]
142. Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-1527. [PMID: 17391318 DOI: 10.1111/j.1572-0241.2007.01187.x]